{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:25:01Z","timestamp":1773044701465,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-024-00952-4","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:02:15Z","timestamp":1720742535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans"],"prefix":"10.1208","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-4701","authenticated-orcid":false,"given":"Min-Soo","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0365-6613","authenticated-orcid":false,"given":"Dagmar M.","family":"Hajducek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-8766","authenticated-orcid":false,"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7977","authenticated-orcid":false,"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1653","authenticated-orcid":false,"given":"Andrea N.","family":"Edginton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"952_CR1","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(S6):1\u2013158.","DOI":"10.1111\/hae.14046"},{"key":"952_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/JBM.S291536","volume":"14","author":"A Ndoumba-Mintya","year":"2023","unstructured":"Ndoumba-Mintya A, Diallo YL, Tayou TC, Mbanya DN. Optimizing Haemophilia Care in Resource-Limited Countries: Current Challenges and Future Prospects. J Blood Med. 2023;14:141\u20136.","journal-title":"J Blood Med"},{"issue":"1","key":"952_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12288-019-01147-0","volume":"36","author":"N Sidharthan","year":"2020","unstructured":"Sidharthan N, Sudevan R. Low Dose Prophylaxis in Hemophilia Care. Indian J Hematol Blood Trans. 2020;36(1):16\u201325.","journal-title":"Indian J Hematol Blood Trans"},{"issue":"8","key":"952_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/rth2.12438","volume":"4","author":"H Kwak","year":"2020","unstructured":"Kwak H, Lee S, Jo S, Kwon YE, Kang H, Choi G, et al. MG1113, a specific anti\u2013tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia. Res Pract Thromb Haemost. 2020;4(8):1301\u201312.","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"952_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/hae.14866","volume":"29","author":"L Malec","year":"2023","unstructured":"Malec L, Matino D. Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review. Haemophilia. 2023;29(6):1419\u201329.","journal-title":"Haemophilia"},{"issue":"1","key":"952_CR6","doi-asserted-by":"publisher","first-page":"2277497","DOI":"10.1080\/16078454.2023.2277497","volume":"28","author":"T Seth","year":"2023","unstructured":"Seth T, Garg K, Mandal PK, Datta A, Verma S, Hanagavadi S, et al. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India. Hematology. 2023;28(1):2277497.","journal-title":"Hematology"},{"issue":"3","key":"952_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/hae.13753","volume":"25","author":"A Brekkan","year":"2019","unstructured":"Brekkan A, Degerman J, J\u00f6nsson S. Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A. Haemophilia. 2019;25(3):408\u201315.","journal-title":"Haemophilia"},{"issue":"10","key":"952_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2022016571","volume":"141","author":"C Ay","year":"2023","unstructured":"Ay C, Kovacevic KD, Kraemmer D, Schoergenhofer C, Gelbenegger G, Firbas C, et al. The von Willebrand Factor-Binding Aptamer Rondaptivon Pegol as a Treatment for Severe and Nonsevere Hemophilia A. Blood. 2023;141(10):1147\u201358.","journal-title":"Blood"},{"issue":"1","key":"952_CR9","doi-asserted-by":"publisher","first-page":"11180","DOI":"10.1038\/s41598-020-68125-9","volume":"10","author":"KD Kovacevic","year":"2020","unstructured":"Kovacevic KD, Buchtele N, Schoergenhofer C, Derhaschnig U, Gelbenegger G, Brostjan C, et al. The Aptamer BT200 Effectively Inhibits von Willebrand Factor (VWF) Dependent Platelet Function After Stimulated VWF Release by Desmopressin or Endotoxin. Sci Rep. 2020;10(1):11180.","journal-title":"Sci Rep"},{"issue":"9","key":"952_CR10","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3324\/haematol.2021.279948","volume":"107","author":"KD Kovacevic","year":"2022","unstructured":"Kovacevic KD, Grafeneder J, Sch\u00f6rgenhofer C, Gelbenegger G, Gager G, Firbas C, et al. The von Willebrand Factor A-1 Domain Binding Aptamer BT200 Elevates Plasma Levels of von Willebrand Factor and Factor VIII: A First-In-Human Trial. Haematologica. 2022;107(9):2121\u201332.","journal-title":"Haematologica"},{"issue":"7","key":"952_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/jth.14822","volume":"18","author":"S Zhu","year":"2020","unstructured":"Zhu S, Gilbert JC, Liang Z, Kang D, Li M, Tarantino PM, et al. Potent and Rapid Reversal of the von Willebrand Factor Inhibitor Aptamer BT200. J Thromb Haemost. 2020;18(7):1695\u2013704.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"952_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/hae.14078","volume":"26","author":"PL Turecek","year":"2020","unstructured":"Turecek PL, Johnsen JM, Pipe SW, O\u2019Donnell JS. the i Psg. Biological Mechanisms Underlying Inter-Individual Variation in Factor VIII Clearance in Haemophilia. Haemophilia. 2020;26(4):575\u201383.","journal-title":"Haemophilia."},{"key":"952_CR13","doi-asserted-by":"crossref","unstructured":"Choin A, Aguila S, Fazavana J, Byrne C, Ward S, O\u2019Sullivan J, et al., editors. Aptamer BT200 prolongs VWF half-life by blocking interaction with macrophage scavenger receptor LRP1. International Society on Thrombosis and Haemostasis; 2023; Montr\u00e9al, Canada.","DOI":"10.1016\/j.rpth.2023.100541"},{"key":"952_CR14","unstructured":"Grifols Biologicals Inc. Package Insert - Alphanate2018. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/alphanate.\u00a0Accessed 21 Apr 2023."},{"issue":"5","key":"952_CR15","doi-asserted-by":"publisher","first-page":"ytad219","DOI":"10.1093\/ehjcr\/ytad219","volume":"7","author":"S Honda","year":"2023","unstructured":"Honda S, Shimahara Y, Chikasawa Y, Ogino H. Hemostatic protocol and risk-reduction surgery for treating coronary artery disease with aortic stenosis in a patient with combined coagulation factor VIII and XI deficiency: a case report. Eur Heart J Case Rep. 2023;7(5):ytad219.","journal-title":"Eur Heart J Case Rep."},{"key":"952_CR16","unstructured":"Beal SL, Sheiner LB, Boeckman AJ, Bauer RJ. NONMEM 7.4 Users Guide1989\u20132018. Available from: https:\/\/nonmem.iconplc.com\/nonmem743\/guides.\u00a0Accessed 22 May 2023."},{"issue":"8","key":"952_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis. CPT Pharmacometrics Syst Pharmacol. 2019;8(8):525\u201337.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"952_CR18","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing2023. Available from: https:\/\/www.R-project.org\/.\u00a0Accessed 20 Mar 2023."},{"issue":"5","key":"952_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to Fit a PK Model with Some Data Below the Quantification Limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"952_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10928-019-09634-7","volume":"46","author":"A McEneny-King","year":"2019","unstructured":"McEneny-King A, Chelle P, Foster G, Keepanasseril A, Iorio A, Edginton AN. Development and Evaluation of a Generic Population Pharmacokinetic Model for Standard Half-Life Factor VIII for Use in Dose Individualization. J Pharmacokinet Pharmacodyn. 2019;46(5):411\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"952_CR21","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1182\/bloodadvances.2020003891","volume":"5","author":"LH Bukkems","year":"2021","unstructured":"Bukkems LH, Heijdra JM, de Jager NCB, Hazendonk HCAM, Fijnvandraat K, Meijer K, et al. Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. Blood Adv. 2021;5(5):1513\u201322.","journal-title":"Blood Adv"},{"issue":"13","key":"952_CR22","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood-2014-08-528398","volume":"125","author":"C Ng","year":"2015","unstructured":"Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015;125(13):2029\u201337.","journal-title":"Blood"},{"issue":"2","key":"952_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40262-019-00809-6","volume":"59","author":"P Chelle","year":"2020","unstructured":"Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, et al. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate\u00ae): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clin Pharmacokinet. 2020;59(2):245\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"952_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/BF01061691","volume":"21","author":"NL Dayneka","year":"1993","unstructured":"Dayneka NL, Garg V, Jusko WJ. Comparison of Four Basic Models of Indirect Pharmacodynamic Responses. J Pharmacokinet Biopharm. 1993;21(4):457\u201378.","journal-title":"J Pharmacokinet Biopharm"},{"key":"952_CR25","doi-asserted-by":"crossref","unstructured":"Lee M, Jeong Y-S, Kim M-S, An K-M, Chung S-J. Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics. Pharmaceutics [Internet]. 2022; 14(6).","DOI":"10.3390\/pharmaceutics14061157"},{"issue":"4","key":"952_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF03261885","volume":"26","author":"GM Keating","year":"2012","unstructured":"Keating GM, Dhillon S. Octocog Alfa (Advate\u00ae): A Guide to Its Use in Hemophilia A. BioDrugs. 2012;26(4):269\u201373.","journal-title":"BioDrugs"},{"issue":"6","key":"952_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/BF01062109","volume":"6","author":"K Yamaoka","year":"1978","unstructured":"Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm. 1978;6(6):547\u201358.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"9","key":"952_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1124\/dmd.122.000968","volume":"51","author":"W Lee","year":"2023","unstructured":"Lee W, Kim M-S, Kim J, Aoki Y, Sugiyama Y. Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic\u2013TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions. Drug Metab Dispos. 2023;51(9):1145.","journal-title":"Drug Metab Dispos"},{"issue":"5309","key":"952_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.276.5309.122","volume":"276","author":"GB West","year":"1997","unstructured":"West GB, Brown JH, Enquist BJ. A General Model for the Origin of Allometric Scaling Laws in Biology. Science. 1997;276(5309):122\u20136.","journal-title":"Science"},{"issue":"5","key":"952_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11598930-000000000-00000","volume":"51","author":"SC McLeay","year":"2012","unstructured":"McLeay SC, Morrish GA, Kirkpatrick CMJ, Green B. The Relationship between Drug Clearance and Body Size. Clin Pharmacokinet. 2012;51(5):319\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"952_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10928-019-09637-4","volume":"46","author":"P Chelle","year":"2019","unstructured":"Chelle P, Yeung CHT, Bonanad S, Morales Mu\u00f1oz JC, Ozelo MC, Meg\u00edasVericat JE, et al. Routine Clinical Care Data for Population Pharmacokinetic Modeling: The Case for Fanhdi\/Alphanate in Hemophilia a Patients. J Pharmacokinet Pharmacodyn. 2019;46(5):427\u201338.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"952_CR32","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s40262-015-0277-z","volume":"54","author":"HS Al-Sallami","year":"2015","unstructured":"Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of Fat-Free Mass in Children. Clin Pharmacokinet. 2015;54(11):1169\u201378.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"952_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40262-017-0622-5","volume":"57","author":"J Sinha","year":"2018","unstructured":"Sinha J, Duffull SB, Al-Sallami HS. A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass. Clin Pharmacokinet. 2018;57(7):781\u201395.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"952_CR34","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1124\/dmd.111.043174","volume":"40","author":"M Michaela","year":"2012","unstructured":"Michaela M, Sebastian S, Bernd L, Lars K, Joerg L. Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling. Drug Metab Dispos. 2012;40(5):892.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"952_CR35","first-page":"314","volume":"12","author":"V Jim\u00e9nez-Yuste","year":"2014","unstructured":"Jim\u00e9nez-Yuste V, Auerswald G, Benson G, Lambert T, Morfini M, Remor E, et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus. 2014;12(3):314\u20139.","journal-title":"Blood Transfus"},{"issue":"3","key":"952_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","volume":"7","author":"PW Collins","year":"2009","unstructured":"Collins PW, Blanchette VS, Fischer K, Bj\u00f6rkman S, Oh M, Fritsch S, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413\u201320.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"952_CR37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","volume":"17","author":"IEM Den Uijl","year":"2011","unstructured":"Den Uijl IEM, Mauser Bunschoten EP, Roosendaal G, Schutgens REG, Biesma DH, Grobbee DE, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011;17(6):849\u201353.","journal-title":"Haemophilia"},{"issue":"14","key":"952_CR38","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","volume":"2","author":"N Machin","year":"2018","unstructured":"Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2(14):1792\u20138.","journal-title":"Blood Adv"},{"issue":"10","key":"952_CR39","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40273-020-00944-0","volume":"38","author":"M Srinivasan","year":"2020","unstructured":"Srinivasan M, White A, Chaturvedula A, Vozmediano V, Schmidt S, Plouffe L, et al. Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development. Pharmacoeconomics. 2020;38(10):1031\u201342.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"952_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/cpt.2051","volume":"110","author":"D Hill-McManus","year":"2021","unstructured":"Hill-McManus D, Marshall S, Liu J, Willke RJ, Hughes DA. Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development. Clin Pharmacol Ther. 2021;110(1):49\u201363.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"952_CR41","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","volume":"25","author":"A Richter","year":"2003","unstructured":"Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25(8):2307\u201335.","journal-title":"Clin Ther"},{"issue":"11","key":"952_CR42","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3111\/13696998.2013.846262","volume":"16","author":"M Evans","year":"2013","unstructured":"Evans M, Jensen HH, B\u00f8gelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ. 2013;16(11):1357\u201365.","journal-title":"J Med Econ"},{"key":"952_CR43","doi-asserted-by":"crossref","unstructured":"Grossman HA, Goon B, Bowers P, Leitz G, Study G. Once-Weekly Epoetin Alfa Dosing Is as Effective as Three Times\u2013Weekly Dosing in Increasing Hemoglobin Levels and Is Associated With Improved Quality of Life in Anemic HIV-Infected Patients. J Acquir Immune Defic Syndr. 2003;34(4).","DOI":"10.1097\/00126334-200312010-00003"},{"issue":"4, Supplement 1","key":"952_CR44","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.bone.2006.01.150","volume":"38","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: Understanding the relationship. Bone. 2006;38(4, Supplement 1):S2\u20136.","journal-title":"Bone."},{"issue":"5","key":"952_CR45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/01.ATV.21.5.731","volume":"21","author":"PW Kamphuisen","year":"2001","unstructured":"Kamphuisen PW, Eikenboom JCJ, Bertina RM. Elevated Factor VIII Levels and the Risk of Thrombosis. Arterioscler Thromb Vasc Biol. 2001;21(5):731\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00952-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-024-00952-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00952-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:04:57Z","timestamp":1724079897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-024-00952-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1208\/s12248-024-00952-4","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Band Therapeutics, LLC. James C Gilbert was an employee and shareholder of Band Therapeutics, LLC. The other authors declared no other conflicts of interest for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"BT200 was an investigational new drug, and this work were purely performed for research purpose. The authors\u2019 discussion or opinion in the manuscript should not be interpreted as the position of their organization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"81"}}